COMPANY

Pathos AI

Keywords: oncology mCRPC (Metastatic Castration-resistant Prostate Cancer) Prostate Cancer

Location: Chicago, IL · source · Oct 15, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series D · $365M · announced May 15, 2025 Company release ↗
Source quote
- May 15, 2025 · Company release ↗
  “Where the Future of Drug Development Begins Where the Future of Drug Development Begins Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI New York”

Raises announced in these releases: $365M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Aug 4, 2026 Partnership Partnership / licensing announced Aug 4, 2026. Source: company's own press page. source ↗
May 15, 2025 Raise Private equity round — Series D: $365M (total, as published), announced May 15, 2025. Source: company's own press page. source ↗
May 15, 2025 Raise Series D · $365M source ↗
Feb 7, 2025 Trial start 1: A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC source ↗
Oct 29, 2024 Raise Private equity round — Series C: $62M (total, as published), announced Oct 29, 2024. Source: company release on GlobeNewswire. source ↗

Jun 30, 2028 (ESTIMATED) · 1 · A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC · NCT06785636

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $427.0M. Last 2 years.

May 15, 2025 Private equity round — Series D: $365M (total, as published), announced May 15, 2025. Source: company's own press page. source ↗
Oct 29, 2024 Private equity round — Series C: $62M (total, as published), announced Oct 29, 2024. Source: company release on GlobeNewswire. source ↗
Aug 4, 2026 Partnership / licensing announced Aug 4, 2026. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06785636	A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC	1	Recruiting	Feb 7, 2025	Jun 30, 2028 (estimated)